Comparing two treatments for acute ischemic stroke

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase III clinical trial investigates two treatment strategies for acute ischemic stroke caused by a large vessel occlusion. Participants will be randomly assigned to receive either direct mechanical thrombectomy or mechanical thrombectomy preceded by intravenous tenecteplase. The study aims to evaluate the effectiveness of these approaches in improving patient outcomes, measured by the modified Rankin scale score at 90 days post-treatment. The trial will include a diverse group of participants across multiple centers, ensuring robust data collection and analysis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Acute ischemic stroke where a patient is eligible for IV thrombolytic treatment within 4.5 hours of stroke onset.
* No significant pre-stroke functional disability (mRS ≤ 1)
* Baseline NIHSS scores obtained before randomization must be equal to or higher than 6 points
* Age equal ≥ 18 and =\< 85 years
* Occlusion (TICI 0-1) of the ICA or proximal MCA segments (M1 or M2) suitable for endovascular treatment, as evidenced by CTA, MRA, or angiogram, with or without concomitant cervical carotid stenosis or occlusion.
* Patient randomized within 4.5 hours of symptom onset. Symptoms onset is defined as the point in time the patient was last seen well (at baseline). Treatment start is defined as groin puncture, max 90 minutes after randomization.

  * Patients who have woken up with the symptoms and who have a mismatch FLAIR-DWI according to the WAKE-UP Trial will be considered as having a time window of \<4.5h.
* Informed consent obtained from the patient or acceptable patient surrogate.

Exclusion Criteria:

* Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR \> 1.7 or direct oral anticoagulants such as thrombin antagonists (ex: dabigatran) or X factor (ex: rivaroxaban, apixaban, edoxaban) at the least 48 hours.
* Baseline platelet count \< 100.000/μL
* Baseline blood glucose of \< 50mg/dL or \> 400mg/dl
* Severe, sustained hypertension (SBP \> 185 mm Hg or DBP \> 110 mm Hg) NOTE: If the blood pressure can be successfully reduced and maintained at the acceptable level using AHA guidelines recommended medication (including iv antihypertensive drips), the patient can be enrolled.
* Patients in coma (NIHSS item of consciousness \>1) (Intubated patients for transfer could be randomized only in case an NIHSS is obtained by a neurologist prior transportation).
* Seizures at stroke onset which would preclude obtaining a baseline NIHSS
* Serious, advanced, or terminal illness with anticipated life expectancy of less than one year.
* History of life-threatening allergy (more than rash) to contrast medium.
* Subjects who has received IV t-PA treatment before the randomization.
* Renal failure with serum creatinine ≥ 3 mg/dl
* Woman of childbearing potential who is known to be pregnant or who has a positive pregnancy test on admission.
* Subject participating in a study involving an investigational drug or device that would impact this study.
* Cerebral vasculitis, endocarditis or subarachnoid hemorrhage.
* Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations.
* Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor from overseas).
* Hypodensity on CT more than one third of MCA territory or hypersignal in more than one third of MCA territory on MR-DWI.
* ASPECTS score \< 6 (no contrast at least 5 mm cut imaging on CT) or on MR-DWI sequence.
* CT or MR evidence of hemorrhage (the presence of \< 5 GRE, SWI, SWAN microbleeds is allowed).
* Significant mass effect with midline shift.
* Evidence of ipsilateral carotid occlusion, high grade stenosis or arterial dissection in the extracranial or petrous segment of the internal carotid artery that cannot be treated or will prevent access to the intracranial clot or excessive tortuosity of cervical vessels precluding device delivery/deployment.
* Subjects with occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior/posterior circulation).
* Evidence of intracranial tumor (except small meningioma).

Where it's running

• Hospital Moinhos de Vento
  Porto Alegre, Rio Grande do Sul, Brazil Recruiting
• Hospital das Clínicas Botucatu
  Botucatu, Brazil Recruiting
• Hospital de Base do Distrito Federal
  Brasília, Brazil Recruiting
• Hospital das Clínicas da UFPR
  Curitiba, Brazil Recruiting
• Hospital Geral de Fortaleza
  Fortaleza, Brazil Recruiting
• Hospital de Clinicas de Porto Alegre
  Porto Alegre, Brazil Recruiting

Study contacts

• Principal investigator: Octavio M Pontes-Neto, MD, PhD — Hospital de Clínicas da Faculdade de Medicina de Ribeirão Preto - Universidade de São Paulo
• Study coordinator: Octavio M Pontes-Neto, MD, PhD
• Email: opontesneto@fmrp.usp.br
• Phone: +551636053779

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effectiveness of a new neurorehabilitation technology for stroke recovery

  This study is testing a new rehabilitation technology that uses robots and virtual reality to see if it can help stroke patients recover better than regular therapy.

  Recruiting Neurotechnika · Samara, Samara Oblast · NCT06753006

• HR-MRI–Directed Tirofiban Therapy for Late-Window ICAS-LAA Stroke

  We’re testing whether tirofiban plus dual antiplatelet therapy, guided by high-resolution MRI of the brain’s blood vessels, can help people with intracranial large-artery atherosclerosis strokes that begin more than 24 hours after onset.

  Recruiting Phase 3 Weifang Medical University · Weifang, China/Shandong Province · NCT07379190

• Emergency Stroke Unit for treating acute strokes

  This study is testing a new Emergency Stroke Unit that uses a mobile MRI to see if it can help treat stroke patients faster and improve their recovery.

  Recruiting Chinese University of Hong Kong · Hong Kong · NCT06728592

• Tenecteplase versus alteplase before mechanical thrombectomy for acute large-vessel ischemic stroke

  This trial tests whether tenecteplase given before mechanical thrombectomy helps adults with acute large-vessel ischemic stroke within 4.5 hours recover better than standard alteplase.

  Recruiting Phase 3 Xuanwu Hospital, Beijing · Beijing, Beijing Municipality · NCT06658197

• Carotid artery stenting during treatment of acute stroke

  This study is testing if adding carotid artery stenting during a stroke treatment can help improve blood flow to the brain and lower the chances of having another stroke for patients with blocked carotid arteries.

  Recruiting Phase 3 University Medical Center Groningen · Groningen · NCT06511089

• Monitoring brain-derived tau levels in acute ischemic stroke patients

  This study is testing how brain-derived tau levels change in stroke patients over 48 hours to see if it can help understand their condition and improve treatment decisions.

  Recruiting Ludwig-Maximilians - University of Munich · Munich, Bavaria · NCT06121336

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.